-
FDA approves update of prescription label information for ammo MM-targeted drug Kyprolis (carzofilmib)
Time of Update: 2020-06-11
recently, Amgen announced that the U.S Food and Drug ( FDA ( FDA) has approved the multiple myeloma (MM) targeted drug Kyprolis (carfilzomib) prescription label information update, including ph
-
FDA approves Mercado PD-1 tumor immunotherapy Keytruda for treatment of hepatocellular carcinoma patients
Time of Update: 2020-06-11
recently, Mercado announced that the U.S FDA (approved its PD-1 tumor immunotherapy Keytruda (Chinese commodity name: Creeda, generic name: Pablo Pearlmono) a new indication for patients with hepa
-
Jansen's innovative drug Stelara (ustekinumab) achieved positive results in Phase 3 clinical trials treating UC adult patients
Time of Update: 2020-06-11
UC and Crohn's disease (CD) are two of the most common inflammatory bowel disease (IBD), both chronic, recurrent, and self-relieving inflammatory progressive digestive tract (GI) disease today, Jan
-
Roche's heavy-duty drug for type A haemophilia, Hemlibra, gets FDA approval
Time of Update: 2020-06-11
type A haemophilia is a serious genetic disease healthy (when a person bleeds, a clotting protein called factor VIII brings together factor IXa and factor X, triggering a clotting process that hel
-
FDA grants ABI-H0731 fast-track determination for treatment of HBV infection patients
Time of Update: 2020-06-11
recently, the U.S FDA , which has been awarded a drug for the treatment of patients with chronic hepatitis B virus (HBV) infection, announced ABI-H0731, a core protein inhibitor for Assembly B
-
Quadripling influenza virus lysatis vaccine approved for market in China
Time of Update: 2020-06-11
yesterday, the State Drug Administration issued a message: four-price influenza virus cracking vaccine in China was approved for market sources said there had been a marked increase in influenza ou
-
Human Fu Pharma Receives "Drug Clinical Trial Approval" for RF-A089 Capsules
Time of Update: 2020-06-11
recently, the Pharmaceutical (issued a notice) said that the " Drug (Clinical Trial ) approved by the State Medicines (the Supervisory Authority) has been issued RF-A089 is jointly applied b
-
Concentric Analgesics' new drug ca-008 for postoperative pain is recognized by FDA for breakthrough therapies
Time of Update: 2020-06-11
Today, Co ncentric Bio medicine (Inc.) (announced that it is the new drug (recognized by the U.S FDA ( a breakthrough therapy the CA-008 developed by the CA- ncentric Analgesics is a non-opi
-
The listing application for the new class 1 drug Malayacid pyridorate and tablets of Hengrui Pharmaceuticals has been reviewed
Time of Update: 2020-06-11
recently, C FDA (official website information shows that Jiangsu Hengrui Pharmaceutical (class new drug (Malay acid pyrideinandini and tablets have been reviewed, is expected to be approved for
-
Veatonite diet drug Belviq helps people lose weight and stay long-term
Time of Update: 2020-06-11
recently, research has shown that Eisai's company , a weight-loss drug, Belviq, can help people lose weight and maintain it for a long time without increasing the risk of heart disease findings w
-
FDA approves Lilly Alimta (injection pemele) with a new indication
Time of Update: 2020-06-11
recently, the U.S Pharmaceuticals announced that the U.S Food and Drug ( FDA ( ) has approved alimta (injection-based pemephore) combined carboplatin and Mercado-1 immunotherapy Keytruda (Pembr
-
FDA approves new adaptation of INVOKANA
Time of Update: 2020-06-11
recently, Johnson and Johnson's Janssen Pharmaceutical (Inc.) (The U.S FDA (approved INVOKANA, canagliflozin) new adaptation to reduce the risk of cardiovascular heart disease, stroke or death
-
FDA approves Braftovi capsule synthe mektovi tablets for treatment of melanoma patients
Time of Update: 2020-06-11
recently, Array BioPharma (announced that the U.S Food and Drug ( FDA () has approved Braftovi (binimetinib), a MEK inhibitor) combined with Mektovi (encorafenib, a BRAF inhibitor) tablet for a
-
FDA approves Mercado-heavy immunotherapy Keytruda (pembrolizumab) to treat patients with advanced cervical cancer
Time of Update: 2020-06-11
recently, the (MSD) of The of Mersadon announced that the U.S FDA approve its heavy immunotherapy, The Keytruda, to treat patients with advanced cervical cancer Keytruda Keytruda is a monoclon
-
FDA approves NEW drug application for JAZZ Pharmaceuticals to repair Xyrem oral solution
Time of Update: 2020-06-11
seizure sleep disorder is a long-term neurological disease in which patients have reduced their ability to regulate sleep/wake cycles Recently, the JAZZ Pharmaceutical s on announced that the u.S
-
Merck has partnered with Xi'an Janssen to launch an innovative adult type 2 diabetes treatment with a new drug, Acoad®
Time of Update: 2020-06-11
China has 114 million people with diabetes, the highest number in the world, according to the 2017 Diabetes Map released by the International Diabetes Federation According to the 2017 edition of Chi
-
FDA approves neurotoxin product Xeomin for treatment of chronic salivation in adult patients
Time of Update: 2020-06-11
salivation is mainly manifested in drooling, a common symptom in patients with neurological disorders, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), cerebral palsy (CD), a
-
FDA approves Rituxan for treatment of adult patients with moderate to severe normal herpes
Time of Update: 2020-06-11
recently, Swiss Pharmaceuticals announced that the U.S Food and Drug ( FDA ( FDA) has approved the treatment of adult patients with moderate to severe normal type of osteophlys (PV) with ritu
-
Gileaddi Paveso Phosphorous Bwe (trade name Harvoni) is about to be approved for listing in China
Time of Update: 2020-06-11
recently, Gileaddi Paeveso phosphorous buwe tablets (trade name Harvoni) in China's import listing application entered the "in the approval" stage, this hepatitis C drug will soon be approved in the
-
Application for FDA approval for supplementary biologics for wet age macular degeneration injection EYLEA
Time of Update: 2020-06-11
AMD is a common age-related eye disease common lying in people over 50 years of age and is the leading cause of vision loss and irreversible vision loss recently, Regeneron Pharmaceuticals announce